Compare Brookfield Infrastructure Partners LP (BIP) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Infrastructure Partners LP vs Moderna, Inc. — how do they compare? Brookfield Infrastructure Partners LP trades at $39 (market cap $18.10B), while Moderna, Inc. trades at $60.38 (market cap $24.18B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Brookfield Infrastructure Partners LP pays a 4.62% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| BIP | MRNA | |
|---|---|---|
Market Cap | $18.10B | $24.18B |
Sector | Industrials | Health |
52-Week High | $42.62 | $81.80 |
52-Week Low | $29.81 | $22.36 |
Enterprise Value | $77.05B | $20.33B |
Dividend Yield | 4.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
